Pulmonary hypertension due to left heart diseases

JL Vachiéry, Y Adir, JA Barberà, H Champion… - Journal of the American …, 2013 - jacc.org
Pulmonary hypertension (PH), a common complication of left heart diseases (LHD), negatively
impacts symptoms, exercise capacity, and outcome. Although the true prevalence of PH-…

Pulmonary hypertension in chronic lung diseases

…, G Simonneau, AU Wells, JL Vachiery - Journal of the American …, 2013 - jacc.org
… IPF/CPFE with PH (mPAP ≥25 mm Hg); PH-COPD, PH-IPF, and PH-CPFE); COPD/IPF/CPFE
with severe PH (mPAP ≥35 mm Hg or mPAP ≥25 mm Hg with low cardiac index [CI <2.0 l

Left ventricular heart failure and pulmonary hypertension

…, A Vonk-Noordegraaf, JL Vachiery - European heart …, 2016 - academic.oup.com
In patients with left ventricular heart failure (HF), the development of pulmonary hypertension
(PH) and right ventricular (RV) dysfunction are frequent and have important impact on …

Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial

N Galiè, M Humbert, JL Vachiéry, CD Vizza… - Journal of the American …, 2002 - jacc.org
Objectives : The purpose of this study was to assess the efficacy and safety of beraprost
sodium, an orally active prostacyclin analogue, in New York Heart Association (NYHA) …

Pulmonary hypertension due to left heart disease

JL Vachiéry, RJ Tedford, S Rosenkranz… - European respiratory …, 2019 - Eur Respiratory Soc
… Conflict of interest: JL. Vachiéry reports consultancy and speaker fees paid to institution, and
is an investigator in clinical trials for Actelion Pharmaceuticals and Bayer, consultancy fees …

Exercise-induced pulmonary hypertension: physiological basis and methodological concerns

…, R Saggar, R Saggar, JL Vachiery… - American journal of …, 2013 - atsjournals.org
Exercise stresses the pulmonary circulation through increases in cardiac output ( Q . ) and left
atrial pressure. Invasive as well as noninvasive studies in healthy volunteers show that the …

Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension

…, R Naeije, P Escribano, N Skoro-Sajer, JL Vachiery - Chest, 2006 - Elsevier
Study objectives The aim of this long-term multicenter analysis was to investigate whether
subcutaneously infused treprostinil could provide sustained improvements of exercise …

Outcome after cardiopulmonary resuscitation in patients with pulmonary arterial hypertension

…, JL Vachiery, A Torbicki, J Behr… - American journal of …, 2002 - atsjournals.org
… The patients in this study had a mean pulmonary artery pressure of 61 mm Hg and a mean
cardiac index of 1.7 L/min/m 2 , indicating severe pulmonary vascular disease. Interestingly, …

Macitentan in pulmonary hypertension due to left ventricular dysfunction

JL Vachiéry, M Delcroix, H Al-Hiti… - European …, 2018 - Eur Respiratory Soc
… For cardiac index, the mean treatment effect at week 12 for macitentan versus placebo was
0.4 L·min −1 ·m −2 (95% CI 0.1–0.7). No change in PAWP or mRAP was observed in either …

Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis …

…, AJ Peacock, G Simonneau, JL Vachiéry… - Annals of the …, 2017 - ard.bmj.com
Background Patients with connective tissue disease-associated pulmonary arterial
hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response …